Who is affected by this change?

This affects Independence Blue Cross Oncology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Apr 1, 2026.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.141d, Tisotumab vedotin-tftv (Tivdak®)

Independence Blue Cross·Oncology·Pharmacy

Effective date

Apr 1, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

Medicare Advantage policy MA08.141d for Tisotumab vedotin-tftv (Tivdak®) has been reissued with an effective date of April 1, 2026. This appears to be a pharmacy policy update, though specific coverage or authorization changes are not detailed in the summary.

Action Required

Action needed

Before April 1, 2026: Billing team should review the full policy details at the provided URL to understand specific changes to Tisotumab vedotin-tftv (Tivdak®) coverage requirements for Medicare Advantage patients. Update billing procedures and prior authorization workflows as needed based on the complete policy text.

Related policy hubs

Independence Blue Cross policies Oncology